Management of mixed acute rejection driven by a de novo donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a kidney recipient: a case report-Reference-Cited by-同舟云学术

Management of mixed acute rejection driven by a de novo donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a kidney recipient: a case report

Published:2021-08-27 Issue:4 Volume:78 Page:244-247
ISSN:0967-4845
Container-title:British Journal of Biomedical Science
language:en
Short-container-title:British Journal of Biomedical Science

Author:

Boix F¹^ORCID,Feito J²^ORCID,Rodríguez-Campón A³,Chillón MC¹^ORCID,García-Sánchez S¹^ORCID,Tabernero G³,Fraile P³,García-Sanz R¹^ORCID

Affiliation:

1. Department of Haematology, University Hospital of Salamanca (HUS-IBSAL), CIBERONC, and Cancer Research Institute of Salamanca-IBMCC (CSIC-USAL University), Salamanca, Spain

2. Department of Clinical Pathology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain

3. Department of Nephrology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain

Funder

Gerencia Regional de Salud

Publisher

Frontiers Media SA

Subject

Infectious Diseases,Biochemistry (medical),Microbiology (medical),Clinical Biochemistry,Immunology,Microbiology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/09674845.2021.1927308

Reference11 articles.

1. The classification and treatment of antibody-mediated renal allograft injury: Where do we stand?

2. Antibody-mediated vascular rejection of kidney allografts: a population-based study

3. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials

4. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies